[vc_row][vc_column][vc_empty_space]
Project Summary
Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patients or when unused medicines are disposed of in an incorrect manner. As APIs are biologically active compounds, concerns have been raised about the potential effects of APIs in the environment on human and environmental health. Over the past 25+ years, a substantial amount of work has been done to determine the occurrence, fate, effects and resulting risks of APIs in the environment, and regulatory schemes have been developed requiring environmental risk assessments of all new APIs. However, for most APIs currently in use, only limited data are available on environmental risks, and for new APIs, the testing schemes may not always be optimal.[/vc_column_text][vc_empty_space][vc_empty_space][vc_custom_heading text=”The aim of iPiE therefore is to develop frameworks that utilize information from toxicological studies, pharmacological mode of action and in silico models to support intelligence-based environmental testing of pharmaceuticals in development and to prioritise legacy pharmaceuticals (those authorized prior to 2006 enactment of Medicines Agency requirements) for targeted environmental risk assessment and/or environmental (bio) monitoring. ” font_container=”tag:h3|font_size:18|text_align:left|color:%23348fcd” google_fonts=”font_family:Open%20Sans%3A300%2C300italic%2Cregular%2Citalic%2C600%2C600italic%2C700%2C700italic%2C800%2C800italic|font_style:400%20italic%3A400%3Aitalic”][vc_empty_space height=”16px”][vc_empty_space][vc_column_text]The aim will be delivered through a number of specific objectives:[/vc_column_text][vc_empty_space][/vc_column][/vc_row][vc_row][vc_column width=”1/4″]To review existing approaches for prioritization of APIs and their intelligent testing based on mode of action and to develop improved frameworks for such purposes.
[/vc_column_text][/vc_column][vc_column width=”1/4″]
To establish a high quality database on the properties, environmental fate characteristics and ecotoxicity of APIs
[/vc_column_text][/vc_column][vc_column width=”1/4″]
To develop methods for estimating external and internal exposure to APIs for different scenarios
[/vc_column_text][/vc_column][vc_column width=”1/4″]
To develop methods and models for predicting ecotoxicological responses to APIs
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][/vc_column][/vc_row][vc_row][vc_column width=”1/4″]
To validate the developed models, concepts and frameworks using targeted experiments
[/vc_column_text][/vc_column][vc_column width=”1/4″]
To develop a software system to support intelligent testing and prioritization of APIs in the environment
[/vc_column_text][/vc_column][vc_column width=”1/4″]
To develop guidance on how the software system and associated predictive tools can be used
[/vc_column_text][/vc_column][vc_column width=”1/4″]
To engage with and exchange knowledge with stakeholder groups throughout the project
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][vc_column_text]These objectives will be delivered by a world leading consortium comprising experts in data management and computational modelling, pharmacology, ecotoxicology, environmental chemistry, predictive (eco)toxicology, prioritization and intelligent testing methodologies and environmental risk assessment.[/vc_column_text][vc_empty_space height=”64px”][/vc_column][/vc_row]